The post hoc analysis of pooled data from the Semaglutide Treatment Effect in People with Obesity (STEP) 1, 2, 3, and 5 trials indicated that semaglutide treatment at 2.4 mg did not increase the risk of depressive symptoms or suicidal ideation compared to placebo, while demonstrating a statistically significant yet clinically negligible decrease in depressive symptoms [75]
Author: Clinical Account Executive Marc Zande, PharmD About Serve You Rx Serve You Rx is a full-service pharmacy benefit manager (PBM) with unquestionable flexibility and an unwavering commitment to doing whats best for its clients
0.9% respectively)
Mounjaro (tirzepatide) is typically dosed weekly, not daily
You do not need to have diabetes to qualify
The FDA and other policymakers should take immediate action to ensure the integrity of the FDA's rigorous regulatory review and approval process, the drug supply chain and decades of carefully balanced approaches to fostering innovation and generic competition. Eli Lilly, Novo Nordisks rival in the diabetes and obesity market, also is expected to launch a weight-loss pill, orforglipron, in the first half of this year
